EVALUATION OF THE STABILITY OF VIGABATRIN IN HOSPITALAR EXTEMPORANEOUS FORMULATIONS by Ayres, Marcio Vinicius et al.
Drug Analytical Research 
ISSN: 2527-2616            Drug Anal Res, 2019; v. 3, n. 01, 51-60 
 
Evaluation of the stability of Vigabatrin in hospitalar extemporaneous formulations 
Márcio Vinícios Ayres*
a
, Nathalie Ribeiro Wingert
b
, Sarah Chagas Campanharo
b
, Elfrides E.S.Schapoval
b
, Martin Steppe
b
 
 
a
 Hospital de Clinicas de Porto Alegre - Pharmacy Service, Porto Alegre, Rio Grande do Sul, Brazil 
b
Universidade Federal do Rio Grande do Sul - Graduate Program in Pharmaceutical Sciences, Porto Alegre, Rio Grande do Sul, 
Brazil 
 
*Corresponding author: martin.steppe@ufrgs.br 
 
The aim of this study was to analyze the chemical stability of the anticonvulsant vigabatrin extemporaneous formulation from 
tablets in storage conditions of different temperatures and types of packaging used. The analysis of vigabatrin extemporaneous 
formulations were performed by high-performance liquid chromatography (HPLC). The method described in British 
Pharmacopoeia was co-validated for specificity, linearity, precision and accuracy. Vigabatrin extemporaneous solutions were 
prepared in triplicate and placed in amber glass and PET bottles, which were stored under three different conditions: at room 
temperature (15 to 30 °C), under refrigeration (2 to 8 °C), and oven (40 °C). Samples of solutions stored at room temperature and 
refrigeration were collected every 7 days along 35 days. The same was done for solutions kept at 40 °C, but for a period of 28 
days. It was also analyzed the solutions pH in each sampling time. Vigabatrin extemporaneous solutions showed variations within 
the limits of British Pharmacopoeia 2016 up to 21 days in amber PET and glass bottles at room and refrigerated temperatures. 
Vigabatrin content for formulations kept in oven decreased above 10% after 7 days of study. The lowest pH change occurred in 
amber glass bottle stored under refrigeration. Results of this study will be applied as a reference for vigabatrin extemporaneous 
formulation in hospital, once it was demonstrated the reliability of storage time interval and proper conditions for the use. Thus, 
pediatric patients with fractionated doses or use of nasogastric probe will have adequately prepared extemporaneous formulations, 
reducing the risk of dilution errors and microbiological contamination, improving the efficacy and safety, and enabling more time 
for nursing assistance. 
Keywords: drug stability; extemporaneous formulation; high-performance liquid chromatography; hospital; vigabatrin. 
 
 
 
Introduction  
 
The most commonly used drugs are in solid pharmaceutical 
form, however, in clinical practice, many patients require 
liquid dosage forms. Many medicinal products, however, are 
not marketed in liquid form and the pharmacist should be 
able to prepare this formulation from the raw material or 
tablets provided that the stability, formulation and 
preparation are well documented [1]. According to Good 
Manipulation Practices in Pharmacies, this transformation or 
extemporaneous formulation is defined as "manipulation of 
pharmaceutical specialty aiming at the preparation of one 
pharmaceutical form from another" [2]. However, changes in 
the pharmaceutical form may lead to changes in 
pharmacokinetic parameters and lead to stability problems, 
and in both cases therapeutic efficacy may be compromised 
[3].  
In the hospital context, considering the numerous drugs 
included in drug selection, it calls attention to those who only 
have solid dosage forms and who do not have information 
about the stability of their formulation. It is these drugs that 
generate the need for adequate information regarding their 
stability and, consequently, therapeutic efficacy. The 
extemporaneous formulation are also widely used to 
administer the drugs in patients using nasoenteric probes for 
both fractionated and whole dose prescription drugs. A study 
conducted at the Hospital de Clinicas de Porto Alegre 
showed that 95% of patients with nasoenteric probes used 
solid dosage forms, mainly tablets (72%). A total of 158 
different drugs were used, and only 23% of them had a liquid 
pharmaceutical form
 
[4]. The routine of prescription, 
preparation and administration of the leads has already been 
implanted and consolidated in the hospital for years and, due 
to the entry of new drugs in the selection of medicines, new 
information is required. Within this hospital context, 
specifically in the anticonvulsive therapy, it is possible to 
observe the use of several drugs in Brazil that have only 
presentation in the solid pharmaceutical form, such as, for 
example, phenytoin and vigabatrin. These drugs should be 
prepared as liquid formulations to suit the dose and facilitate 
administration to pediatric patients, however, there is no 
literature data regarding the stability of these drugs after 
formulation. Considering the use of vigabatrin in the hospital 
therapeutic arsenal, together with the lack of data related to 
the stability of the formulations and their specific use in 
anticonvulsant therapy, the present study aims to evaluate the 
behavior of this drug in solution. Thus, establishing the 
reliable time interval for their use with, as well as verify the 
most appropriate storage conditions.  
Vigabatrin is chemically described as 4-amino-5-hexenoic 
acid. It has a molecular weight of 129.16 and its molecular 
formula is C6H11NO2
       
[5,6]. It was synthesized in 1974 and 
was the first antiepileptic drug to be created with a 
mechanism of action specifically determined from the 
beginning of its development [7]. Vigabatrin is an amino acid 
analogous to gamma-aminobutyric acid (GABA). It is a 
racemic mixture formed by two enantiomers, but with only 
the active S (+). It is a selective and irreversible inhibitor of 
GABA-transaminase, the enzyme that degrades GABA and, 
thereby, increases GABA levels in the central nervous 
system, reducing excitability
 
[8, 9, 10]. 
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Methods 
 
Samples 
 
Vigabatrin standard substance used had a declared content of 
99.4% and the vigabatrin 500 mg tablets used in the study 
were of the Sabril
®
 brand. Each tablet contains 500 mg of 
vigabatrin and the excipients are: polyvinylpyrrolidone 
(Povidone K30), microcrystalline cellulose, sodium starch 
glycolate, hydroxypropylmethylcellulose (hypromellose), 
magnesium stearate, titanium dioxide and polyethylene 
glycol 8000 (Macrogol 8000). In the covalidation of the 
method, a reference solution of 1.2 mg/mL vigabatrin was 
prepared and the vigabatrin sample solution from the tablet 
was also prepared in a concentration of 1.2 mg/mL 
(Specificity). In the stability study, the concentration of 
vigabatrin for solution reference and samples used was 1.0 
mg/mL. The mobile phase used in the analysis was also the 
solvent for the formulation of these solutions. 
 
Analytical proccedures 
 
Analysis of vigabatrin was performed using the method 
described in the British Pharmacopoeia (2016). The system 
suitability, specificity, linearity, precision and accuracy tests 
were performed in order to verify the reproducibility of the 
pharmacopoeial method in high performance liquid 
chromatography (HPLC). The tests for system suitability, 
linearity, precision and accuracy were developed in high 
performance liquid chromatograph (HPLC Agilent, 1200 
series model) and the specificity test was performed in other 
HPLC (Shimadzu, 20A model). The column used in the 
covalidation for separation was a cationic SCX. The mobile 
phase was composed of ultrapure water and potassium 
phosphate monobasic PA to prepare the 0.025 M phosphate 
solution. This solution had the pH adjusted to 2.8 with 
orthophosphoric acid. After, methanol and acetonitrile were 
added to the phosphate solution. The final ratio was 
1000:40:4 (v/v/v) phosphate buffer pH 2.8, methanol and 
acetonitrile, respectively.  
The system suitability was verified during the analysis of the 
linearity, observing the results in the concentration of 1.0 
mg/mL, through the following parameters: retention factor 
(k), repeatability (RSD), tailing factor (TF) and number of 
theoretical plates (N)
 
[11]. To verify the specificity of the 
method, vigabatrin standard and the simulated sample of the 
excipients specified in the package leaflet were used. The 
solution of the simulated excipient sample was prepared from 
weighing the equivalent of the excipients contained in the 
mean weight of ten vigabatrin tablets, subtracting the amount 
of active substance. The obtained solutions were analyzed for 
their chromatographic profile to verify possible interferences 
of the excipients at the peak related to vigabatrin. The 
linearity of the method was evaluated by constructing a 
standard curve containing six different concentrations for 
three consecutive days. Solution reference of vigabatrin 1.2 
mg/mL was diluted to obtain concentrations of 0.2 mg/mL; 
0.4 mg/mL; 0.6 mg/mL; 0.8 mg/mL and 1.0 mg/mL, 
respectively. For each concentration, readings were 
performed in triplicate. The standard curve was constructed 
using a concentration versus absolute area graph. The 
equation of the line was determined from the linear 
regression by least squares method. Precision was determined 
by the inter-repeatability, intermediate precision and by the 
calculation of the relative standard deviation (RSD) obtained 
from the analyzes performed during the determination of 
linearity on three consecutive days. Accuracy was 
determined using solution reference of vigabatrin at the 
concentration of 1.2 mg/mL and vigabatrin sample at a 
concentration of 1.2 mg/mL. For the recovery test, three 
reference solutions were prepared, obtaining the 
concentrations 0.75 mg/mL, 0.90 mg/mL and 1.20 mg/mL, 
respectively. 
 
Stability Study of Vigabatrin extemporaneous formulations  
 
Samples for the stability study were prepared in a vertical 
laminar flow chamber. Eighteen flasks with a capacity of 100 
ml were used to prepare the samples, nine amber glass and 
nine polyethylene terephthalate (PET) bottles. In each of the 
eighteen flasks were added a 500 mg vigabatrin tablet and 
100 mL water for injection with syringe aid, sealed with cap 
and shaken for dissolution of the tablets, resulting in the 
concentration of 5 mg/mL. After they were separated and 
labeled by stability study group, as follows: 
- three amber glass bottles for stability study in refrigerated 
temperature (2 to 8 ° C);  
- three bottles of amber PET for stability study in refrigerated 
temperature (2 to 8 °C); 
- three amber glass bottles for stability study at room 
temperature (15 to 30 °C); 
- three bottles of amber PET for stability study at room 
temperature (15 to 30 °C); 
- three amber glass bottles for stability study in temperature 
at 40 °C; 
- three bottles of amber PET for stability study in temperature 
at 40 °C. 
 
The refrigerator and room temperatures were monitored and 
recorded daily. The microbiological oven was fixed at              
40 °C for the stability study. Samples were collected every 7 
days for a period of 35 days for the stability study of glass 
and amber PET bottles at refrigerated and ambient 
temperature. Samples stored in oven were collected every 7 
days for a period of 28 days for the stability study of the 
glass bottles and amber PET in an oven at a temperature of 
40 °C. Two mL of each sample vial (5.0 mg/mL) were 
collected with the aid of an automatic pipet and added in a 10 
mL volumetric flask. The volume was completed with mobile 
phase, resulting in the final concentration of 1.0 mg/mL. All 
collected samples were analyzed by HPLC at each collection 
time, together with standard reference vigabatrin prepared at 
the concentration of 1.0 mg/mL. The pH check was 
performed every 7 days on the vigabatrin samples prepared 
and left under the same conditions. The procedure was 
carried out for the period of 35 days for the samples stored in 
refrigerated and ambient temperature and, for 28 days, for 
samples stored in an oven. 
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Results and Discussion 
 
Evaluation of the analysis method 
 
Table 1 shows the results of the system suitability parameters 
obtained by the chromatographic method during covalidation 
(linearity) at the concentration of 1.0 mg / mL vigabatrin. 
The specificity of the chromatographic method was evaluated 
by comparing the chromatograms obtained (vigabatrin 
standard, excipient mixture and vigabatrin extemporaneous 
formulation) in order to verify the possible interference of the 
excipients in the determination of vigabatrin. It was observed 
that there is no interference of the adjuvants components of 
the tablet, because they had less retention time than 
vigabatrin. Figure 1 shows the chromatogram of vigabatrin 
standard substance and figures 2 and 3 show the 
chromatograms of the simulated excipient sample and the 
vigabatrin extemporaneous formulation, respectively.  
 
Table 1. System suitability parameters recommended for HPLC in 
covalidation and those obtained experimentally for vigabatrin 
analysis11. 
Parameters Proposed Values found 
Retention factor (k) k > 2 10.48 
Repeatability (RSD) RSD < 1%  0.43 
Resolution (Rs) Rs > 2 29.04a 
Tailing factor (TF) TF ≤ 2 1.14 
Nuber of plates (N) > 2000 (HPLC) 5930 
aIn relation to the solvent peak.   
   
 
 
 
Figure 1. Chromatogram of vigabatrin standard substance at the 1.0 
mg/mL concentration obtained by HPLC in the Shimadzu apparatus, 
model 20 A. 
 
 
Figure 2. Chromatogram of the simulated excipient sample 
obtained by HPLC in the Shimadzu, model 20A equipment. 
 
 
Figure 3. Chromatogram of vigabatrin tablet preparation at 1.0 
mg/mL concentration obtained by HPLC in the Shimadzu 
apparatus, model 20 A. 
 
 
Table 2 shows the experimental values of absolute areas of 
vigabatrin, referring to the concentration range used for 
vigabatrin by HPLC. The graphical representation of the 
standard curve of vigabatrin standard substance, obtained by 
the HPLC technique, is shown in figure 4. 
 
 
 
Table 2. Absolute areas of vigabatrin standard substance obtained 
by HPLC to determine the standard curve. 
Concentration 
(mg/mL) 
Area b RSD 
0.2 52.00 1.899 
0.4 106.70 2.085 
0.6 154.20 1.327 
0.8 208.50 0.655 
1.0 263.80 1.013 
1.2 313.90 1.008 
bEach value represents the average of the triplicates of the 
determinations carried out in three days. 
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Figure 4. Graphical representation of the standard curve of 
vigabatrin standard substance obtained by HPLC. 
 
The experimental values obtained in the determination of 
vigabatrin standard substance by HPLC are described in table 
3, from the determination of the repeatability and 
intermediate accuracy performed in triplicate for three 
consecutive days. The experimental values for the accuracy 
calculated through the recovery test are shown in table 4. 
 
 
Table 3. Experimental values obtained in the determination of 
accuracy from vigabatrin standard substance. 
Concentration 
(mg/mL) 
Day Area
c 
RSD 
(intraday) 
RSD 
(interday) 
 1 52.60 0.66  
0.2 2 52.17 1.82 2.04 
 3 51.20 3.04  
 1 209.97 0.60  
0.8 2 207.53 0.34 0.65 
 3 207.97 0.26  
 1 313.13 0.35  
1.2 2 310.87 0.28 1.01 
 3 317.83 0.13  
cEach value represents the average of the triplicates of the 
determinations carried out in three days. 
 
Table 4. Experimental values obtained in the determination of 
recovery accuracy from vigabatrin tablets. 
 Sample 
concentration 
(mg/mL) 
Concentration 
found 
(mg/mL)d 
Recovery 
(%) 
RSD 
SR1 0.75 0.71 94.22 0.82 
SR2 0.90 0.87 96.30 0.67 
SR3 1.20 1.17 97.22 0.49 
dThe value represents the average of three determinations. 
 
 
Stability of Vigabatrin extemporaneous formulations  
 
Table 5 shows the experimental values obtained by HPLC of 
the vigabatrin extemporaneous formulations, prepared at the 
concentration of 1.0 mg/mL and packed in amber glass 
bottles and amber PET bottles, stored under refrigeration (2 
to 8 °C) and evaluated for a period of 35 days. Figure 5 
shows the values of the vigabatrin concentration versus time, 
stored in an amber glass bottle and under refrigeration. 
Figure 6 shows the values of vigabatrin concentration versus 
time, stored in an amber PET bottle and under refrigeration. 
Table 6 shows the experimental values obtained by HPLC of 
the vigabatrin extemporaneous formulations, prepared at the 
concentration of 1.0 mg/mL and packed in amber glass 
bottles and amber PET bottles, stored at room temperature 
(15 to 30 °C) and evaluated for a period of 35 days. Figure 7 
shows the vigabatrin concentration versus time stored in an 
amber glass bottle at room temperature. Figure 8 shows the 
concentration of vigabatrin versus time stored in an amber 
PET bottle at room temperature. Table 7 shows the 
experimental values obtained by HPLC of the vigabatrin 
extemporaneous formulations, prepared at the concentration 
of 1.0 mg/mL and conditioned in amber glass bottles and 
amber PET bottles, stored at a temperature of 40 °C and 
evaluated for a period of 28 days. Figures 9 and 10 represent 
vigabatrin concentration versus time values stored in amber 
glass bottle and amber PET bottle, respectively, at 40 °C. The 
pH values for the measurements performed at each time are 
described in table 8. The graphical representation of pH 
values is shown in figure 11. 
 
Table 5. Results of mean concentrations of vigabatrin stored in 
amber glass bottles and amber PET bottles under refrigeration (2 to 
8 ° C) analyzed by HPLC at the specified times. 
Mean concentration (mg/mL) 
Time 
(days) 
Glass 
bottlee 
RSD 
PET 
bottlee 
RSD 
0 1.0092 0.06 1.0092 0.06 
7 1.0129 0.64 1.0177 0.79 
14 0.9925 0.60 1.0126 0.72 
21 1.0022 0.44 0.9885 0.39 
28 0.8918 0.82 0.8987 0.45 
35 0.8754 0.14 0.8734 0.18 
eEach value represents the mean of the triplicates of the 
determinations. 
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Figure 5. Graphical representation of the concentration of 
vigabatrin stored in an amber glass bottle under refrigerated 
temperature versus time. 
 
 
 
 
Figure 6. Graphical representation of the concentration of 
vigabatrin stored in an amber PET bottle under refrigerated 
temperature versus time. 
 
 
Table 6. Results of mean vigabatrin concentrations stored in amber 
glass bottles and amber PET bottles at room temperature (15 to 30 ° 
C), analyzed by HPLC at the specified times. 
Mean concentration (mg/mL) 
Time 
(days) 
Glass bottle 
f 
RSD 
PET bottle 
f 
RSD 
0 1.0092 0.06 1.009 0.06 
7 1.0202 0.23 1.0083 0.21 
14 1.0251 0.63 1.0206 1.74 
21 0.9953 0.72 0.9815 0.42 
28 0.9101 0.70 0.9027 0.42 
35 0.8862 0.37 0.8822 0.10 
fEach value represents the mean of the triplicates of the 
determinations. 
 
 
 
 
Figure 7. Graphical representation of the concentration of 
vigabatrin stored in an amber glass bottles at room temperature 
versus time. 
 
 
 
Figure 8. Graphical representation of the concentration of 
vigabatrin stored in an amber PET bottle at room temperature versus 
time. 
 
 
Table 7. Results of mean concentrations of vigabatrin stored in 
amber glass bottles and amber PET bottles in an oven (40 ° C) 
analyzed by HPLC at the specified times. 
Mean concentration (mg/mL) 
Time 
(days) 
Glass bottle g RSD PET bottle 
g RSD 
0 1.0092 0.06 1.0092 0.06 
7 0.8889 0.15 0.8828 0.15 
14 0.8797 0.10 0.9123 0.44 
21 0.8848 0.08 0.8960 0.15 
28 0.8822 0.04 0.8906 0.19 
gEach value represents the mean of the triplicates of the 
determinations. 
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Figure 9. Graphical representation of the concentration of 
vigabatrin stored in an amber glass bottle at 40 ° C versus time. 
 
 
Figure 10. Graphical representation of the concentration of 
vigabatrin stored in an amber PET bottle at 40 ° C versus time. 
 
Table 8. pH values found in the vigabatrin extemporaneous 
formulation, depending on the type of packaging material and the 
mode of storage. Table legend: TA (room temperature); TR 
(refrigerated temperature); T40 (oven temperature); G (glass bottle); 
P (PET bottle). 
Time (days) 
0 7 14 21 28 35 Temperature/ 
Material 
TA/P 6.97 6.28 6.22 6.21 6.15 5.73 
TA/G 7.13 6.47 6.33 6.26 6.24 5.64 
TR/P 6.94 6.93 7.16 7.08 6.97 6.55 
TR/G 7.25 7.14 7.06 7.24 7.07 7.21 
T40/P 6.89 6.49 6.27 6.20 6.18 5.68 
T40/G 6.89 6.62 6.33 6.24 6.24 5.65 
 
 
 
Figure 11. Graphical representation of the pH of VIGABATRIN 
stored in glass vial and amber PET under refrigerated temperature, 
ambient and oven at 40 ° C versus time. Graph legend: TA (room 
temperature); TR (refrigerated temperature); T40 (oven 
temperature); V (glass bottle); P (PET bottle). 
 
Evaluation of the analysis method by HPLC 
 
Suitability of the system 
Before developing the validation analyzes, it should be 
established that the HPLC system and procedures are capable 
of yielding data of acceptable quality. These tests are used to 
verify that system resolution and repeatability are adequate. 
The suitability of the system is the control of a system to 
ensure adequate performance before or during the analysis
 
[11]. According to the results indicated in table 1, the 
suitability parameters evaluated are in accordance with the 
pertinent literature and qualify the method of vigabatrin 
analysis. 
Specificity 
Specificity or selectivity is the ability to unequivocally 
evaluate the substances under consideration in the presence 
of components that may interfere with their determination in 
a complex sample [12]. The specificity of the method was 
evaluated by comparing the chromatograms obtained 
(standard substance and excipients), allowing to evaluate the 
interference of the excipients. The analysis of the 
chromatograms of Figures 1, 2 and 3 indicates that there is no 
interference of the excipients with the vigabatrin signal. The 
chromatographic peak around 4 minutes refers to the 
excipient polyvinylpyrrolidone (PVP), as previously cited by 
CHEN [13]. Therefore, the proposed method has adequate 
specificity. 
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Linearity 
Linearity corresponds to the ability of the method to provide 
results directly proportional to the concentration of the test 
substance within a given application range [12]. Figures 5 
and 6 present the vigabatrin chromatograms at concentrations 
of 0.2 mg/mL and 1.2 mg/mL, respectively, representing the 
lowest and highest concentration of the curve in the linearity 
graph. This range of concentrations was used by CHEN
 
to 
verify the linearity at the wavelength of the study (210 nm) 
[13]. According to figures 4, 5 and 6 it can be observed that 
proportionality occurred between the range of concentrations 
and their respective peak areas. In previous covalidation 
analysis, concentrations below 0.2 mg/mL were found to be 
poorly detected. This is due to the lack of a chromophore 
group in the vigabatrin molecule, which makes it difficult to 
detect by spectrophotometric absorption
 
[14]. The linearity of 
the method presented coefficient of correlation (r) equal to 
0.9999, therefore, satisfactory to the criteria established by 
RE 899 of ANVISA
 
[15]. 
Precision 
Precision represents the dispersion of results between 
independent, repeated assays of the same sample, similar 
sample or patterns, under defined conditions
 
[12]. Three 
points of the linearity curve were evaluated. The lowest 
concentration (0.2 mg/mL), the mean concentration (0.8 
mg/mL) and the highest concentration (1.2 mg/mL), 
according to table 2. Repeatability (intraday) and 
intermediate (interday) showed a RSD of less than 5%. 
Therefore, the result is satisfactory and meets the criteria of 
RE 899, demonstrating adequate repeatability and 
reproducibility [15]. 
Accuracy 
Accuracy represents the degree of agreement between the 
individual results found in a given trial and a reference value 
accepted as true
 
[12]. According to the analysis performed by 
CHEN, the mean recovery obtained was 99.8% with RSD of 
1.4% [13]. According to Table 3, the accuracy showed a 
mean recovery percentage of 95.9% and mean RSD of 
0.66%. These results indicate that the method has adequate 
accuracy. 
Stability of Vigabatrin extemporaneous formulations 
Many variables influence the chemical stability of drugs. 
Specifically in this study, the influence of temperature and 
the type of packaging material were evaluated. The 
concentration of the vigabatrin sample at time zero was 
1.0092 mg/mL and RSD was 0.06%, indicating that the 
initial concentration of vigabatrin was in agreement with the 
concentration of standard substance. In the evaluation of 
vigabatrin shunts in glass bottles and amber PET bottles at 
refrigerated temperature (Figures 7 and 8), it is possible to 
observe that the 1.0 mg/mL concentration of vigabatrin was 
reduced until the maximum study time of 35 days. There was 
a percentage reduction of the vigabatrin concentration of 
13.26% and 13.46% in amber glass bottles and amber PET 
bottles, respectively, from time zero to the time of 35 days. 
The percentage difference in the reduction of the vigabatrin 
concentration between the types of packaging material of the 
bottles was only 0.20%. At refrigerated temperature, (figures 
7 and 8), it is verified that up to the time of 21 days there was 
a percentage decrease in the concentration of vigabatrin of 
only 0.69% and of 2.05% in the bottles of amber glass and 
PET, respectively. When the 28-day time is observed, a more 
abrupt reduction occurs for both vials, with a drop of 11.63% 
and 10.95% in amber glass bottles and amber PET bottles, 
respectively, comparing them with the concentration of 
vigabatrin at time zero. In the evaluation of the shunts of 
vigabatrin in amber glass bottle and amber PET bottle at 
room temperature (figures 7 and 8), there was a percentage 
reduction of the vigabatrin concentration of 12.19% and of 
12.58% in amber glass bottles and amber PET bottle, 
respectively, from time zero to the time of 35 days. The 
percentage difference of the reduction between the types of 
packaging material of the bottles was 0.39%. At room 
temperature, observing figures 9 and 10, it was observed that 
up to the time of 21 days there was a percentage decrease in 
the concentration of vigabatrin of only 1.38% and of 2.74% 
in amber glass bottles and amber PET bottles, respectively. 
When the 28-day time was observed, as in the refrigerated 
temperature, a more abrupt reduction occurred for both 
flasks, dropping 9.82% and 10.55% in amber glass bottles 
and amber PET bottles, respectively, comparing them with 
the vigabatrin concentration at time zero, at room 
temperature. According to the British Pharmacopoeia, the 
variation in the concentration of vigabatrin allowed in tablets 
is ± 5%.  
Considering this parameter and evaluating the results, it was 
observed that these values do not represent a significant 
decrease of the initial content, demonstrating vigabatrin 
stability up to the 21 days time for the refrigerated and 
ambient temperature conditions, as well as for the type of 
material of packaging (amber glass and PET) [16]. In the 
evaluation of the shunts of vigabatrin in a glass bottle and 
amber PET bottle in an oven at 40 ° C (Figures 11 and 12), 
there was a more pronounced percentage reduction of the 
vigabatrin concentration from the time of 7 days. The 
decrease in vigabatrin concentration was 11.92% and 12.52% 
in amber glass bottles and amber PET bottle, respectively, 
from time zero to time of 7 days. The percent reduction from 
time zero to the time of 28 days was 12.58% and 11.75% in 
amber glass bottles and amber PET bottles, respectively, 
indicating that the concentration of vigabatrin after the 
reduction observed in the time of 7 days, remained 
practically constant. Temperature is one of the primary 
factors affecting drug stability
 
[17]. The choice of 
temperatures to perform the stability study was to verify if 
the study drug was stable at the most usual temperatures to 
store the medicines (refrigerated and environment), and to 
verify if the higher temperature would influence the stability 
of vigabatrin. In addition to temperature, the second most 
important variable in drug degradation is pH. The effect of 
pH on the degradation of drugs in aqueous solutions has been 
well studied. It can be explained by the catalytic action that 
the H
+
 and OH
-
 ions can exert on various chemical reactions
 
[17]. The evaluation of the pH of the vigabatrin leads (Figure 
13) showed that, at room temperature, there was a 17.79% 
reduction in the amber PET bottle and a 20.90% reduction in 
the amber glass bottle. In refrigerated temperature, a lower 
pH variation occurred, where a reduction of 5.62% was 
 
Drug Anal Res, 2019; v. 3, n. 01, 51-60 
 
58 
observed in amber PET bottles and only 0.55% in amber 
glass bottles. The pH reduction with the greatest variation 
between zero time and 35 days occurred at room temperature 
and in both types of packaging materials. At the temperature 
of 40 ° C it was observed that in both types of packaging 
concomitant reduction of pH occurred. In the amber glass 
bottle there was a reduction of pH in 18% of time zero until 
the time of 35 days. In the amber PET bottle, pH reduction 
occurred at 17.56% of time zero until the time 35 days. 
Therefore, there is only 0.44% difference between the types 
of packaging material. Lowering the pH may suggest an early 
drug degradation process, although the production 
degradation products, as well as significant reduction of the 
drug content, have not occurred.  
At all temperatures analyzed, no chromatographic peaks were 
formed related to a possible degradation process at the 
collection times. According to CHEN, the primary 
degradation product of vigabatrin is 5-ethenyl-2-pyrrolidone 
and in analysis by HPLC, the retention time of the 
chromatographic peak of this product is about 5 minutes [13]. 
Packaging plays an important role in maintaining quality and 
it is crucial that stability tests of the dosage forms in the final 
package are carried out. The role of packaging is to protect 
the pharmaceutical form of light, moisture and oxygen, as 
well as exposure to other types of factors that may influence 
the quality of the final product. However, pharmaceutical 
products may interact with the packaging material and the 
concentration of the active substances may be reduced by 
adsorption, absorption or incorporation by the packaging 
material
 
[17]. The results regarding the types of packaging 
material showed a variation of less than 1% in all 
temperatures studied, suggesting that there was no significant 
difference between the glass and PET packages. This study 
did not aim to conduct chemical kinetics studies of the 
degradation of vigabatrin. Due to the limited literature on the 
stability of vigabatrin, the results could already predict 
whether or not the factors studied could interfere with the 
stability of the derivation of this drug. 
Applicability of Vigabatrin extemporaneous formulations 
for hospital use 
 
Extemporaneous formulations for hospital use require 
stability data to ensure efficacy and safety of the drug for a 
short period of use. Due to the variability in dosage and 
dosage of prescriptions of patients, especially pediatric 
patients, in addition to frequent changes of these, the leads 
are prepared for a few days. In addition, as recommended in 
RDC 67/2007 of ANVISA, formulation are considered to be 
extemporaneous formulations and should be prepared for 
only 48 hours if chemical stability is proven [2]. In a hospital 
environment, in order to guarantee patient safety, this short 
term refers to the microbiological stability of the formulation. 
Observing the results of this chemical stability study, 
vigabatrin could be incorporated into the routine for the 
formulation of the Hospital de Clinicas formulation, in 
response to a long-standing demand from the care team 
regarding the difficulty in preparing and administering this 
drug to the patient. Broadening the view of the topic, it is 
important to emphasize that due to the entry of new drugs 
into the therapeutic arsenal, further stability studies will be 
needed. It is not only studies of chemical stability of the drug 
derived from a tablet or capsule, but of possible interactions 
with other drugs, with the patient's diet, chemical 
compatibility when administered by nasoenteric tube among 
other variables found in the hospital environment, showing 
how much is relationship. Therefore, it is important for the 
pharmacist to be attentive to the needs of the patient, most of 
times identified through the nursing team that provides direct 
assistance, preparing and administering the latter's 
medications. More importantly, in addition to identifying 
these needs, the pharmacist seeks solutions that impact on 
improved care, focusing on patient safety. Such needs are not 
only characteristics of Brazil, but a global problem. 
Following the advent of thalidomide, the pharmaceutical 
industry has launched several licensed adult medications on 
the market, stating that more studies in children will be 
needed or that it has not been evaluated for such use. This 
situation considers pediatric patients as "therapeutic 
orphans", making the prescription of doses, from a newborn 
patient to the adolescent patient, difficult for the physician to 
determine, often extrapolating the adult dose
 
[18, 19]. There 
is a worldwide critique of pharmaceutical laboratories, 
regarding the lack of presentations of medicines directed to 
pediatric patients, as well as adequate information regarding 
dose and dosage, considering the differentiated physiology 
during each stage of the child's development. Thus, there is 
not generation of scientific information that meets the 
requirements and promotes authorization of medicines for 
use in the pediatric population through regulatory agencies
 
[18, 20]. A study by CUZZOLIN has shown that, despite 
changes in regulatory agencies in the United States and in the 
European Community, creating policies and stimulating 
pharmacological research in pediatrics, few studies have been 
directed at newborns. However, there was an increase in the 
registration of medicines directed to pediatrics, reducing the 
need for medicines derived or manipulated, but still, 
insufficient [19]. 
According to the World Health Organization (WHO), 
essential medicines as those for pediatric use should be a 
priority in research. However, these drugs continue to be 
used without this information
 
[20]. Vigabatrin is a real 
example of this problem. In Brazil, only the tablet 
presentation is recorded. The powder is not registered for the 
extemporaneous formulation of the oral solution, as it is in 
Europe, where it is specifically used to facilitate the 
administration of the prescribed dose and improve the 
palatability of the medicine, thus ensuring greater safety for 
the pediatric patient. At the national level, issues related to 
the marketing interest of pharmaceutical companies, or even 
the lack of specific demands of regulatory bodies, still lack 
appropriate answers. Another important aspect that arises is 
the variability of modes of formulation of a drug when it is 
necessary to prepare it. Due to the lack of information in the 
literature on stability, formulations, compatibility among 
others, there is no standard formulation with these aspects 
taken care of. In addition, the use of excipients that have a 
toxic effect on newborns corroborates this concern
 
[20]. A 
prospective study of 117 master pharmacies (commercial and 
institutional) showed that the formulation of caffeine citrate 
solution 20 mg/mL used formulations with different 
excipients, demonstrating the concern of WHO cited above 
[21]. Therefore, the stability study of vigabatrin contemplated 
only the use of water for the formulation of the leads. In the 
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routine of Hospital de Clinicas, the leads are prepared with 
water for injections only without the use of other excipients, 
since the leads are prepared as extemporaneous formulations. 
In rare exceptions, when there is a need for masking of 
flavor, contact of the nurse or clinical pharmacist requests the 
extemporaneous formulation with simple syrup or syrup with 
flavoring. In these cases, it is verified in the stability study of 
the drug in question, if there is information of 
incompatibility. Several drugs do not be mixed with syrup 
because sucrose promotes chemical interaction. It is the case 
of the Maillard reaction that occurs between reducing sugars 
and the primary amino group of amino acids, for example
 
[17]. Another important aspect is the formulation of referrals 
that pose a risk to the personnel involved, such as cytotoxic 
drugs. Care with individual protection and specific area, 
appropriate for the formulation, are necessary to guarantee 
the safety of those involved in the process [18]. The RDC 
67/2007 of ANVISA is the legislation that specifies the 
necessary conditions for each group of medicines, where 
Annex VI regulates on the manipulation of formulation in the 
master pharmacy [2]. Therefore, despite the efforts of 
regulatory agencies in other countries to stimulate studies 
involving the use of medicines in the pediatric population, 
there is still little in relation to needs. In Brazil, there is still a 
lack of many presentations of medicines that attend to this 
public, leading necessarily to extemporaneous formulations 
of tablets and capsules, in order to meet the therapeutic needs 
of pediatrics. Therefore, the search for information regarding 
stability studies of pediatric formulations is unavoidable and 
efforts in this regard are still needed.  
 
Conclusions  
 
The vigabatrin did not show reduction of content higher than 
specified in the British Pharmacopoeia 2016, up to the time 
of 21 days, at room temperature and refrigerated. The 
variation of vigabatrin content between the type of packaging 
(glass and PET) in the time of 21 days is less than 1%, at 
room temperature and refrigerated; The results obtained may 
serve as a subsidy for extemporaneous pediatric formulations 
of vigabatrin in the hospital routine, guaranteeing greater 
safety in the formulation and efficacy in the treatment of 
epileptic syndromes. 
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